Recursion Pharmaceuticals (RXRX) ended the recent trading session at $6.36, demonstrating a -6.33% change from the preceding day's closing price. This change lagged the S&P 500's daily loss of 0.63%.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Pinker's new book reveals how recursive mentalizing—thinking about thinking—may be the hidden engine of human life, from ...

Abstract: This article studies the recursive state estimator-based fuzzy adaptive control scheme for discrete-time uncertain nonlinear systems with state saturations and missing measurements. A fuzzy ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage ...

In the latest close session, Recursion Pharmaceuticals (RXRX) was down 5.42% at $5.23. The stock fell short of the S&P 500, which registered a loss of 0.38% for the day. Meanwhile, the Dow experienced ...

Abstract: This article is concerned with a recursive remote estimation problem for a class of nonlinear complex networks subject to the token bucket protocol (TBP) and amplify-and-forward (AF) relays.

Recursion Pharmaceuticals (NASDAQ: RXRX), a biotech focused on artificial intelligence (AI), became a publicly traded company in 2021 -- a time when AI did not grab nearly as much attention (if any at ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

In recent days, Recursion Pharmaceuticals attracted heightened attention as traders responded to the stock’s very large short interest, alongside the announcement of a $12.5 million milestone payment ...